Modelling HIV-1 2-LTR dynamics following raltegravir intensification

A model of reservoir activation and viral replication is introduced accounting for the production of 2-LTR HIV-1 DNA circles following antiviral intensification with the HIV integrase inhibitor raltegravir, considering contributions of de novo infection events and exogenous sources of infected cells, including quiescent infected cell activation. The model shows that a monotonic increase in measured 2-LTR concentration post intensification is consistent with limited de novo infection primarily maintained by sources of infected cells unaffected by raltegravir, such as quiescent cell activation, while a transient increase in measured 2-LTR concentration is consistent with significant levels of efficient (R0 > 1) de novo infection. The model is validated against patient data from the INTEGRAL study and is shown to have a statistically significant fit relative to the null hypothesis of random measurement variation about a mean. We obtain estimates and confidence intervals for the model parameters, including 2-LTR half-life. Seven of the 13 patients with detectable 2-LTR concentrations from the INTEGRAL study have measured 2-LTR dynamics consistent with significant levels of efficient replication of the virus prior to treatment intensification.

[1]  Alan S. Perelson,et al.  A Novel Antiviral Intervention Results in More Accurate Assessment of Human Immunodeficiency Virus Type 1 Replication Dynamics and T-Cell Decay In Vivo , 2003, Journal of Virology.

[2]  D. Ho,et al.  Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission , 1996, Journal of virology.

[3]  Michael J. Piovoso,et al.  Modeling Uncertainty in Single-Copy Assays for HIV , 2012, Journal of Clinical Microbiology.

[4]  B. Gazzard,et al.  Identification of two mutually exclusive groups after long-term monitoring of HIV DNA 2-LTR circle copy number in patients on HAART , 2003, AIDS.

[5]  Linqi Zhang,et al.  Rapid Turnover of 2-LTR HIV-1 DNA during Early Stage of Highly Active Antiretroviral Therapy , 2011, PloS one.

[6]  J. Murray.  HIV Dynamics and Integrase Inhibitors , 2009, Antiviral chemistry & chemotherapy.

[7]  Luís M A Bettencourt,et al.  The estimation of the effective reproductive number from disease outbreak data. , 2009, Mathematical biosciences and engineering : MBE.

[8]  C. Yoder,et al.  Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression , 2000, AIDS.

[9]  John L. Sullivan,et al.  Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy , 2000, Nature Medicine.

[10]  Anthony S. Fauci,et al.  Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy , 2000, Nature Medicine.

[11]  Yang Wang,et al.  Evidence that Low-Level Viremias during Effective Highly Active Antiretroviral Therapy Result from Two Processes: Expression of Archival Virus and Replication of Virus , 2005, Journal of Virology.

[12]  John W. Mellors,et al.  No Effect of Raltegravir Intensification on Viral Replication Markers in the Blood of HIV-1–Infected Patients Receiving Antiretroviral Therapy , 2012, Journal of acquired immune deficiency syndromes.

[13]  Jeffrey N. Martin,et al.  Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals , 2010, AIDS.

[14]  B. Clotet,et al.  Treatment Intensification with Raltegravir in Subjects with Sustained HIV-1 Viraemia Suppression: A Randomized 48-Week Study , 2012, Antiviral therapy.

[15]  B. Masquelier,et al.  Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells. , 2010, The Journal of antimicrobial chemotherapy.

[16]  R. Siliciano,et al.  Biomarkers of HIV replication , 2010, Current opinion in HIV and AIDS.

[17]  J. Pawlotsky,et al.  Multicenter Performance Evaluation of a New TaqMan PCR Assay for Monitoring Human Immunodeficiency Virus RNA Load , 2006, Journal of Clinical Microbiology.

[18]  France Mentré,et al.  Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: Application to HIV dynamics model , 2006, Comput. Stat. Data Anal..

[19]  C. B. Hare,et al.  Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy , 2010, AIDS.

[20]  N. Dziuba,et al.  Quantitative PCR used to Assess HIV-1 Integration and 2-LTR Circle Formation in Human Macrophages, Peripheral Blood Lymphocytes and a CD4+ Cell Line , 2010, Virology Journal.

[21]  Haihong Zhu,et al.  Parameter Identifiability and Estimation of HIV/AIDS Dynamic Models , 2008, Bulletin of mathematical biology.

[22]  J. Tobin.  Estimation of Relationships for Limited Dependent Variables , 1958 .

[23]  D. Richman,et al.  2-LTR circular viral DNA as a marker for human immunodeficiency virus type 1 infection in vivo. , 1994, Virology.

[24]  E. Mariman,et al.  Variation in protein levels obtained from human blood cells and biofluids for platelet, peripheral blood mononuclear cell, plasma, urine and saliva proteomics , 2009, Genes & Nutrition.

[25]  Anthony S. Fauci,et al.  AIDS: Re-emergence of HIV after stopping therapy , 1999, Nature.

[26]  Ryan Zurakowski,et al.  A compartment based model for the formation of 2-LTR circles after raltegravir intensification , 2012, 2012 IEEE 51st IEEE Conference on Decision and Control (CDC).

[27]  R. Siliciano,et al.  Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir , 2009, Antiviral therapy.

[28]  D M Bortz,et al.  Model Selection and Mixed-Effects Modeling of HIV Infection Dynamics , 2006, Bulletin of mathematical biology.

[29]  J. Mellors,et al.  Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  Martin Hemberg,et al.  Quantification of mRNA in single cells and modelling of RT-qPCR induced noise , 2008, BMC Molecular Biology.

[31]  A. Perelson,et al.  Dynamics of HIV infection of CD4+ T cells. , 1993, Mathematical biosciences.

[32]  R. Colgrove,et al.  A combinatorial ledge: reverse transcriptase fidelity, total body viral burden, and the implications of multiple-drug HIV therapy for the evolution of antiviral resistance. , 1999, Antiviral research.

[33]  H Putter,et al.  A Bayesian approach to parameter estimation in HIV dynamical models , 2002, Statistics in medicine.

[34]  D. Richman,et al.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.

[35]  John M. Coffin,et al.  Clonal Sequences Recovered from Plasma from Patients with Residual HIV-1 Viremia and on Intensified Antiretroviral Therapy Are Identical to Replicating Viral RNAs Recovered from Circulating Resting CD4+ T Cells , 2011, Journal of Virology.

[36]  D. Hazuda,et al.  Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase , 2007, AIDS.

[37]  M. Markowitz,et al.  Absence of HIV-1 Evolution in the Gut-Associated Lymphoid Tissue from Patients on Combination Antiviral Therapy Initiated during Primary Infection , 2012, PLoS pathogens.

[38]  C. Cobelli,et al.  On parameter and structural identifiability: Nonunique observability/reconstructibility for identifiable systems, other ambiguities, and new definitions , 1980 .

[39]  Alan S. Perelson,et al.  Bayesian Analysis of a Population HIV Dynamic Model , 2002 .

[40]  Sarah Palmer,et al.  HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects , 2010, Nature Medicine.

[41]  R. Lempicki,et al.  HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Sarah Palmer,et al.  Can HIV infection be eradicated through use of potent antiviral agents? , 2010, Current opinion in infectious diseases.

[43]  C. Van Lint,et al.  HIV Persistence and the Prospect of Long-Term Drug-Free Remissions for HIV-Infected Individuals , 2010, Science.

[44]  F. Bushman,et al.  Human Immunodeficiency Virus cDNA Metabolism: Notable Stability of Two-Long Terminal Repeat Circles , 2002, Journal of Virology.

[45]  Tara L. Kieffer,et al.  Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. , 2004, The Journal of infectious diseases.

[46]  Yassine Taoufik,et al.  The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution , 2004, AIDS.

[47]  Hulin Wu,et al.  Missing time‐dependent covariates in human immunodeficiency virus dynamic models , 2002 .

[48]  Marie Davidian,et al.  Nonlinear Models for Repeated Measurement Data , 1995 .

[49]  Hua Liang,et al.  Comparison of Linear, Nonlinear and Semiparametric Mixed‐effects Models for Estimating HIV Dynamic Parameters , 2004 .

[50]  S J Gange,et al.  Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[51]  Thomas Greenough,et al.  Episomal Viral cDNAs Identify a Reservoir That Fuels Viral Rebound after Treatment Interruption and That Contributes to Treatment Failure , 2011, PLoS pathogens.

[52]  E. Tse,et al.  On the identifiability of parameters , 1971, CDC 1971.

[53]  Tara L. Kieffer,et al.  Intrinsic Stability of Episomal Circles Formed during Human Immunodeficiency Virus Type 1 Replication , 2002, Journal of Virology.

[54]  Hulin Wu,et al.  Statistical methods for HIV dynamic studies in AIDS clinical trials , 2005, Statistical methods in medical research.

[55]  Claus O. Wilke,et al.  Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4+ T Cells , 2006, Journal of Virology.

[56]  E. Vonesh,et al.  Linear and Nonlinear Models for the Analysis of Repeated Measurements , 1996 .

[57]  F. Bushman.  Measuring covert HIV replication during HAART: the abundance of 2-LTR circles is not a reliable marker. , 2003, AIDS.

[58]  Michael J. Piovoso,et al.  HIV Model Parameter Estimates from Interruption Trial Data including Drug Efficacy and Reservoir Dynamics , 2012, PloS one.

[59]  J Witek,et al.  Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. , 1999, JAMA.

[60]  L. Skovgaard.  NONLINEAR MODELS FOR REPEATED MEASUREMENT DATA. , 1996 .

[61]  Joseph A Kovacs,et al.  ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia , 2007, PLoS pathogens.

[62]  R. Siliciano,et al.  HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. , 2001, JAMA.

[63]  S J Gange,et al.  Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy , 2009, Proceedings of the National Academy of Sciences.

[64]  Xiaohua Xia,et al.  On Identifiability of Nonlinear ODE Models and Applications in Viral Dynamics , 2011, SIAM Rev..

[65]  D. Richman,et al.  In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues , 1997, Journal of virology.

[66]  F. Maldarelli,et al.  Targeting viral reservoirs: ability of antiretroviral therapy to stop viral replication , 2011, Current Opinion in HIV and AIDS.

[67]  D. Armbruster,et al.  Limit of blank, limit of detection and limit of quantitation. , 2008, The Clinical biochemist. Reviews.

[68]  Tara L. Kieffer,et al.  Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. , 2005, JAMA.

[69]  Thomas C. Quinn,et al.  Continued Production of Drug-Sensitive Human Immunodeficiency Virus Type 1 in Children on Combination Antiretroviral Therapy Who Have Undetectable Viral Loads , 2004, Journal of Virology.

[70]  John W. Mellors,et al.  New Real-Time Reverse Transcriptase-Initiated PCR Assay with Single-Copy Sensitivity for Human Immunodeficiency Virus Type 1 RNA in Plasma , 2003, Journal of Clinical Microbiology.

[71]  R. Paredes,et al.  Deep Molecular Characterization of HIV-1 Dynamics under Suppressive HAART , 2011, PLoS pathogens.

[72]  Hulin Wu,et al.  Differential Equation Modeling of HIV Viral Fitness Experiments: Model Identification, Model Selection, and Multimodel Inference , 2009, Biometrics.

[73]  Hulin Wu,et al.  Hierarchical Bayesian inference for HIV dynamic differential equation models incorporating multiple treatment factors , 2010, Biometrical journal. Biometrische Zeitschrift.

[74]  Jon Cohen.  HIV/AIDS research. Tissue says blood is misleading, confusing HIV cure efforts. , 2011, Science.